Gross margin
66.1% Fiscal year 2025
Rank 77 of 100: higher than 77% of 370 peers (All). strong.
Rank 62 of 100: higher than 62% of 49 peers (Sector). medium.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Health Care · Fundamental analysis
Metrics from daily candles, as of Nov 20, 2026 · Extended universe
Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year
Illumina is a US maker of gene sequencing technology. The company sells instruments and consumables that labs use to read genetic material, for example for research, cancer diagnostics and prenatal testing. Customers are universities, hospitals and pharmaceutical companies. As of Oct 13, 2026
Illumina develops sequencing and array-based solutions that can be used to analyze genetic material. The company was founded in California in 1998, has been incorporated in Delaware since 2000 and is headquartered in San Diego. Its customers include genome research centers, universities, government labs and hospitals as well as pharmaceutical and biotech companies, diagnostic labs and consumer genetic testing providers. In 2025 most of the revenue came from consumables such as reagents and flow cells, and the rest from instruments as well as services and other. Illumina sells directly in North America, Europe, Latin America and the Asia-Pacific region, and in some markets also through distributors.
Automatically summarized from SEC annual report (10-K, filed Feb 12, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis
Illumina, Inc. · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 12, 2026.
For you first Dividend
The company pays no dividend.
Dividend at a glance Dividends and buybacks per year “Dividend” check What matters for dividend investors
For you first Valuation
There is currently no comparison of the P/E with its own history (for example too few comparable annual values).
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free
Valuation against its own history Valuation over time Comparison with the sector What matters for value investors
For you first Growth
How strongly revenue and earnings per share have grown over the years.
“Growth” check Figures over time Consistency What matters for growth investors
For you first Quality
How much of revenue remains and whether profit arrives as cash.
“Quality” check Earnings quality What matters for quality investors
For you first Trading
The overview of this stock shows the trend by timeframe.
To the overview Chart patterns of this stock What matters for traders
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 28, 2025
66.1% Fiscal year 2025
Rank 77 of 100: higher than 77% of 370 peers (All). strong.
Rank 62 of 100: higher than 62% of 49 peers (Sector). medium.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
18.6% Fiscal year 2025
Rank 58 of 100: higher than 58% of 470 peers (All). medium.
Rank 62 of 100: higher than 62% of 54 peers (Sector). medium.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
19.6% Fiscal year 2025
Rank 76 of 100: higher than 76% of 584 peers (All). strong.
Rank 74 of 100: higher than 74% of 63 peers (Sector). strong.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
31.2% Fiscal year 2025
Rank 81 of 100: higher than 81% of 544 peers (All). strong.
Rank 84 of 100: higher than 84% of 54 peers (Sector). strong.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
12.8% Fiscal year 2025 (total assets at year end)
Rank 84 of 100: higher than 84% of 594 peers (All). strong.
Rank 79 of 100: higher than 79% of 63 peers (Sector). strong.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
41.0% Fiscal year 2025
Rank 57 of 100: higher than 57% of 595 peers (All). medium.
Rank 45 of 100: higher than 45% of 63 peers (Sector). medium.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
21.4% Fiscal year 2025
Rank 80 of 100: higher than 80% of 465 peers (All). strong.
Rank 76 of 100: higher than 76% of 61 peers (Sector). strong.
Median Health Care: 14.5%
Free cash flow divided by revenue.
931.0M USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
−1.8% per year
Rank 16 of 100: higher than 16% of 578 peers (All). weak.
Rank 14 of 100: higher than 14% of 62 peers (Sector). weak.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
+6.0% per year
Rank 34 of 100: higher than 34% of 549 peers (All). medium.
Rank 36 of 100: higher than 36% of 60 peers (Sector). medium.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
+6.9% per year
Rank 55 of 100: higher than 55% of 412 peers (All). medium.
Rank 29 of 100: higher than 29% of 50 peers (Sector). weak.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
+4.1% per year
Rank 25 of 100: higher than 25% of 399 peers (All). weak.
Rank 33 of 100: higher than 33% of 47 peers (Sector). medium.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
+5.8% per year
Rank 33 of 100: higher than 33% of 375 peers (All). medium.
Rank 34 of 100: higher than 34% of 46 peers (Sector). medium.
Median Health Care: +9.3%
Growth of earnings per share per year, adjusted for stock splits.
9 of 9 Fiscal year 2025
Rank 98 of 100: higher than 98% of 310 peers (All). strong.
Rank 96 of 100: higher than 96% of 47 peers (Sector). strong.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
0.55 at fiscal year end
Rank 57 of 100: lower than 57% of 486 peers (All). medium.
Rank 57 of 100: lower than 57% of 50 peers (Sector). medium.
Median Health Care: 0.66
Long-term financial debt divided by equity.
2.08 at fiscal year end
Rank 75 of 100: higher than 75% of 513 peers (All). strong.
Rank 69 of 100: higher than 69% of 63 peers (Sector). strong.
Median Health Care: 1.58
Current assets divided by current liabilities.
+5.4% in 5 years
Rank 25 of 100: lower than 25% of 507 peers (All). weak.
Rank 11 of 100: lower than 11% of 59 peers (Sector). weak.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 4.3B USD · Net income 850.0M USD · Net margin 19.6%
How has it gone since the last annual report?
Revenue in the quarter to Sep 2026 +4.2% vs. the same quarter a year earlier; grown for 5 quarters in a row.
| Quarter | Revenue | vs. year ago | Net income | Margin |
|---|---|---|---|---|
| Jul–Sep 26 | 1.1B | +4.2% | 220.0M | 19.5% |
| Apr–Jun 26 | 1.2B | +9.4% | 207.0M | 17.9% |
| Jan–Mar 26 | 1.1B | +4.8% | 134.0M | 12.3% |
| Oct–Dec 25* | 1.2B | +5.0% | 334.0M | 28.8% |
| Jul–Sep 25 | 1.1B | +0.4% | 150.0M | 13.8% |
| Apr–Jun 25 | 1.1B | −4.8% | 235.0M | 22.2% |
| Jan–Mar 25 | 1.0B | −3.3% | 131.0M | 12.6% |
| Oct–Dec 24* | 1.1B | −1.6% | 186.0M | 16.8% |
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 27, 2026, filed on Oct 30, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Profit is backed by cash; interest is well covered.
| FY | Cash flow ÷ profit | Interest coverage | Tax rate |
|---|---|---|---|
| 2025 | 1.27x | 8.0x | 21.7% |
| 2024 | – | negative | – |
| 2023 | – | negative | – |
| 2022 | – | negative | – |
| 2021 | 0.72x | negative | 13.8% |
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
In 10 fiscal years 3 loss years and 4 years with lower revenue.
| FY | Revenue vs. prior year | Net margin |
|---|---|---|
| 2025 | −0.7% | 19.6% |
| 2024 | −2.9% | −28.0% |
| 2023 | −1.7% | −25.8% |
| 2022 | +1.3% | −96.1% |
| 2021 | +39.7% | 16.8% |
| 2020 | −8.6% | 20.3% |
| 2019 | +6.3% | 28.3% |
| 2018 | +21.1% | 24.8% |
| 2017 | +14.8% | 26.4% |
| 2016 | +8.0% | 19.3% |
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Of 100 USD of revenue, 66.1 USD gross profit, 18.6 USD operating income and 19.6 USD net income remained.
Net income is above operating income (e.g. a tax benefit, gains on investments or securities).
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 4.3B USD | 100.0% |
| Gross profit | 2.9B USD | 66.1% |
| Cost of revenue | 1.5B USD | 33.9% |
| Operating income | 807.0M USD | 18.6% |
| Research & development | 967.0M USD | 22.3% |
| Other operating expenses | 1.1B USD | 25.2% |
| Net income | 850.0M USD | 19.6% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
The operating margin stayed roughly the same in 5 years (18.6%).
Gross marginOperating marginNet marginReturn on equity rose in 5 years from 14.0% to 31.2%.
Return on equityReturn on assetsThe equity ratio fell in 5 years from 61.9% to 41.0%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases. Definition changes: some years use a different debt tag.The current ratio fell in 5 years from 3.60 to 2.08.
Current ratioFree cash flow stayed roughly the same in 5 years (931.0M USD).
Operating cash flowCapital expenditureFree cash flow in USDThe share count rose in 5 years by 5.4% – more new shares were issued than repurchased (dilution).
Diluted share countFrom annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
Revenue rose in 5 years from 3.2B USD to 4.3B USD.
ILMN in USDEarnings per share rose in 5 years from 4.45 USD to 5.45 USD.
ILMN USD per shareThe share count rose in 5 years by 5.4% – more new shares were issued than repurchased (dilution).
ILMNSource: SEC filings, fiscal years up to Dec 28, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
There is currently no comparison of the P/E with its own history (for example too few comparable annual values).
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free
Source: SEC filings and our daily candles
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Over 5 years, 858.0M USD went back to shareholders, 100% of it through share repurchases. That is 36% of the free cash flow of those years. This was offset by new shares issued for 290.0M USD (including employee plans).
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USDDividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Illumina, Inc. next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | 29.4B USD | +3.6% | 78.8% | 34.0% | 28.9% | 37.5% | 38.5% | 32.1% | 8/9 |
| SYK Stryker Corporation | 25.1B USD | +11.8% | 64.0% | 19.5% | 12.9% | 14.5% | 46.9% | 17.1% | 6/9 |
| DHR Danaher Corporation | 24.6B USD | +2.0% | 59.1% | 19.1% | 14.7% | 6.9% | 62.9% | 21.4% | 7/9 |
| REGN Regeneron Pharmaceuticals | 14.3B USD | +11.0% | – | 24.9% | 31.4% | 14.4% | 77.1% | 28.4% | – |
| VRTX Vertex Pharmaceuticals | 12.0B USD | +14.1% | 86.2% | 34.8% | 32.9% | 21.2% | 72.8% | 26.6% | – |
| ISRG Intuitive Surgical | 10.1B USD | +18.2% | 66.0% | 29.3% | 28.4% | 16.0% | 87.1% | 24.7% | – |
| ILMN Illumina, Inc. this stock | 4.3B USD | +6.0% | 66.1% | 18.6% | 19.6% | 31.2% | 41.0% | 21.4% | 9/9 |
| MRNA Moderna | 1.9B USD | +19.3% | 55.3% | −158.1% | −145.2% | −32.6% | 70.1% | −106.2% | 2/9 |
| NVAX Novavax | 1.1B USD | +18.8% | 93.5% | 40.3% | 39.2% | – | −10.9% | −22.3% | 5/9 |
| Median of the sector 27 symbols | 44.3B USD | +8.4% | 67.2% | 18.2% | 14.6% | 14.3% | 38.5% | 15.8% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Compare with the closest peer in the sector ILMN next to MRNA – quality checks, metrics and depth side by side.
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
+6.0% per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 6.0% per year on average, but more slowly than the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
+5.3% per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: +4.1% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 5.3% per year on average, but more slowly than the median company in the sector (+5.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
19.6% last fiscal year
Sector Health Care: median 13.9% (26 symbols)
What does this mean? Of every 100 USD in revenue, 19.57 USD remained as profit – at least as much as the median company in the sector (13.9%). Five years ago the margin was 20.3%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
0.57 latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.57 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
– Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
7 of 10 fiscal years with a profit
What does this mean? In 7 of the last 10 fiscal years the bottom line showed a profit. 3 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 28, 2025 | 4.3B | 850.0M | 19.6% | 5.45 | – | – |
| 2024 | Dec 29, 2024 | 4.4B | −1.2B | −28.0% | −7.69 | – | – |
| 2023 | Dec 31, 2023 | 4.5B | −1.2B | −25.8% | −7.34 | – | – |
| 2022 | Jan 1, 2023 | 4.6B | −4.4B | −96.1% | −28.00 | – | – |
| 2021 | Jan 2, 2022 | 4.5B | 762.0M | 16.8% | 5.04 | – | – |
| 2020 | Jan 3, 2021 | 3.2B | 656.0M | 20.3% | 4.45 | – | – |
| 2019 | Dec 29, 2019 | 3.5B | 1.0B | 28.3% | 6.74 | – | – |
| 2018 | Dec 30, 2018 | 3.3B | 826.0M | 24.8% | 5.56 | – | – |
| 2017 | Dec 31, 2017 | 2.8B | 726.0M | 26.4% | 4.92 | – | – |
| 2016 | Jan 1, 2017 | 2.4B | 462.6M | 19.3% | 3.07 | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q3/26 | Sep 27, 2026 | 1.1B | 220.0M | 19.5% | 1.43 | – | – |
| Q2/26 | Jun 28, 2026 | 1.2B | 207.0M | 17.9% | 1.35 | – | – |
| Q1/26 | Mar 29, 2026 | 1.1B | 134.0M | 12.3% | 0.87 | – | – |
| Q4/25* | Dec 28, 2025 | 1.2B | 334.0M | 28.8% | – | – | – |
| Q3/25 | Sep 28, 2025 | 1.1B | 150.0M | 13.8% | 0.98 | – | – |
| Q2/25 | Jun 29, 2025 | 1.1B | 235.0M | 22.2% | 1.49 | – | – |
| Q1/25 | Mar 30, 2025 | 1.0B | 131.0M | 12.6% | 0.82 | – | – |
| Q4/24* | Dec 29, 2024 | 1.1B | 186.0M | 16.8% | – | – | – |
| Q3/24 | Sep 29, 2024 | 1.1B | 705.0M | 65.3% | 4.42 | – | – |
| Q2/24 | Jun 30, 2024 | 1.1B | −2.0B | −178.8% | −12.48 | – | – |
| Q1/24 | Mar 31, 2024 | 1.1B | −126.0M | −11.7% | −0.79 | – | – |
| Q4/23* | Dec 31, 2023 | 1.1B | −176.0M | −15.7% | – | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $270.2M2 people | −$270.2M |
| 6 months | $00 people | $672.0M5 people | −$672.0M |
| 12 months | $23.6K1 person | $720.6M5 people | −$720.6M |
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
3 of 26 tracked superinvestors report a position.
| Investor | Weight in portfolio | vs. previous quarter | As of |
|---|---|---|---|
| Cathie Wood ARK Investment Management | 1.3% | −18.5% reduced | Q3 2026 |
| Renaissance Technologies | 0.3% | −20.3% reduced | Q3 2026 |
| Bridgewater Associates | < 0.1% | −93.9% reduced | Q3 2026 |
Sold out in the latest quarter: Steve Cohen.
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
We do not calculate a trend score for symbols in the extended universe.
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.
No posts on ILMN yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules